84 results about "Self aggregate" patented technology

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and / or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and / or cosmetic active agent per unit area of the film.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component which includes polyethylene oxide, optionally blended with at least one additional polymer. The films may alternatively contain a polymer component which includes polyvinyl alcohol, optionally blended with at least one additional polymer. The films also may contain a pharmaceutical and / or cosmetic active agent.

The present invention provides a method for the covalent immobilization of biomolecules on polymers for delivery of the biomolecules, which has the advantage of being simple, highly efficient, environmentally friendly and free of side products relative to traditional immobilization techniques. The invention provides a modified micro / nanoparticle system, which uses a functionalized polymer formed into micro or nanoparticles to bind a molecule to the particles using uses facile chemistry, the Diels-Alder cycloaddition between a diene and a dienophile with the polymer being functionalized with one of them and the molecule with the other, or the Huisgen 1,3-dipolar cycloaddition between a terminal alkyne and an azide to bind the molecule to the particle. The molecules and / or other therapeutic agents may be encapsulated within the polymer particles for intravenous therapeutic delivery. The invention also provides a novel synthetic biodegradable polymer, a furan / alkyne-functionalized poly(trimethylene carbonate) (PTMC)-based polymer, whose composition can be designed to meet the defined physical and chemical property requirements. In one example, the particle system self-aggregates from functionalized PTMC-based copolymers containing poly(ethylene glycol) (PEG) segments. The composition of the copolymers can be designed to meet various particle system requirements, including size, thermodynamic stability, surface PEG density, drug encapsulation capacity and biomolecule immobilization capacity.

The invention relates to a method for transferring a nano-layer (1) from a first substrate (5, 105) to a second substrate (30, 130), wherein the nano-layer (1) comprises a self-aggregating monolayer with cross-linked phenyl units and / or a mono-atomic graphite layer (graphene), wherein the method comprises the following steps:a. applying a transfer medium (20, 120) onto nano-layer (1), wherein in this step or afterwards the transfer medium (20, 120) is transformed from a liquid or gaseous phase in a solid phase;b. separating the transfer medium (20, 120) and the nano-layer (1) from the first substrate (5, 105); andc. applying the transfer medium (20, 120) and the nano-layer (1) onto the second substrate (30, 130); andd. removing the transfer medium (20, 120).

This invention relates to films incorporating high amounts of pharmaceutical agents and methods for the preparation of the same. Moreover, the invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a pharmaceutical and / or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and / or cosmetic active agent per unit area of the film.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and / or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and / or cosmetic active agent per unit area of the film.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a topical active agent.

The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

A cartilage-like biomaterial is bioengineered by using a self-aggregating suspension cell culture with hydrostatic mechanical force without the use of a scaffold or foreign matrix for cell attachment during culture. The cells in suspension culture may be preconditioned prior to application of the hydrostatic mechanical force, such as hydrostatic pressure, for a period of time in the range of about 1 week to about 10 weeks. The cartilage-like biomaterial shares critical structural, phenotype, and functional characteristics with native, intact cartilage tissue.

The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.

The invention discloses an ultra-long-life room temperature phosphorescent material and a preparation method and application thereof. The preparation method comprises: uniformly mixing an amine compound and concentrated phosphoric acid in a solvent to obtain a mixed reaction liquid, rapidly heating the mixed reaction liquid to 100 to 200 DEG C, and then performing post treatment to obtain the ultra-long-life room temperature phosphorescent material. The phosphorescent material can emit visible green phosphorescence and delayed fluorescence after the excitation of ultraviolet light is stopped.A decay life is 1.18s. The naked eye resolution time is 10s or more. The phosphorescent properties are stable. The acid and base resistance and photobleaching performances are good. The phosphorescentmaterial has a high yield. The preparation method has fast and simple processes, does not need complicated and expensive equipment and is easy to industrialize. The carbon dots are self-aggregated, the triplet state is effectively and stably excited in the solid state and the oxygen is isolated. The phosphorescent material is bright, has a long phosphorescence life and is free of combination andcoating with other bases.

Purification of recombinant proteins is performed by expressing in a host cell a fusion protein comprising: (a) a product protein domain, (b) an intein, and (c) at least one aggregator protein domain, wherein the aggregator protein domain comprises a self-aggregating protein such as elastin-like proteins (ELPs).

The invention relates to the technical field of biomedical materials and in particular relates to a preparation method of aquatic fish skin collagen hydrogel. The preparation method comprises the following steps: fully dissolving the aquatic fish skin collagen in an acetic acid solution with concentration of 0.5mol / L under the condition of continuous stirring at 4 DEG C to prepare a collagen solution; centrifuging the collagen solution after dissolution, and collecting the supernatant for later use; adjusting the pH value of the collagen supernatant with a filtered sodium hydroxide solution or mixing a filtered phosphate buffer solution with the collagen supernatant in a volume ratio of 1:1, continuously stirring the mixed solution, and then adjusting the pH value of the mixed solution with the filtered sodium hydroxide solution; putting the collagen supernatant mixed solution after the pH value is adjusted in a die, and then standing for 1-2 hours in a water bath at 30-40 DEG C so that the collagen supernatant mixed solution self aggregates, solidifies and is formed; taking the formed hydrogel out of the die, and soaking the hydrogel in ultrapure water for 20-30 minutes, thus obtaining the aquatic fish skin collagen hydrogel. The preparation method has the beneficial effects that the preparation process is simple, the materials are cheap and accessible, and the product is widely applied.

There is described a bio-compatible aqueous slurry for forming a fluid-tight barrier on a surface of a porous implantable article. This aqueous slurry includes a self-aggregating protein comminutate having a substantially uniform particle size, a bio-compatible plasticizer and water. This aqueous slurry is further characterized by having a viscosity of about 8,000 centipoise to about 60,000 centipoise at 25° C. and a pH sufficient to maintain the protein suspended in the slurry.

The present invention relates to a method for production and purification of polypeptides. In particular, the present invention relates to a fusion protein comprising a solubility-enhancing peptide tag moiety, a self-aggregating peptide moiety and a moiety of target peptide and to a method for production and purification of target peptides through expressing said fusion protein.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and / or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and / or cosmetic active agent per unit area of the film.

The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and / or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and / or cosmetic active agent per unit area of the film.

The invention relates to an aggregating sorting TopK inquiry processing method and system. The method includes: receiving an aggregating sorting TopK inquiry request; by each distributed data node, performing local data aggregating according to the inquiry request, and asynchronously transmitting self aggregated data to a central processing node; by the central processing node, using a data structure combined by a hash table and a binary balancing tree to perform data combination on the aggregated data of the distributed data nodes, and using an approximate high frequency item statistical algorithm to count so as to obtain a high frequency item table after aggregating and sorting; outputting the high frequency item table. The method and system is good in flexibility, high in inquiry efficiency, and good in distribution adaptability.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and / or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and / or cosmetic active agent per unit area of the film.